Japan's Kyowa Hakko Kirin Tests New Antibody Type For Many Cancers
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin of Japan says it has begun U.S. clinical trials on a cancer drug that works similarly to targeted antibodies, but without their side effects, such as hair loss. The firm hopes to have the drug on the market late next year. The drug is based on a newly discovered synthetic compound that interferes with a protein responsible for the proliferation of many types of cancer cells. The company also is counting on the drug to provide the benefits of antibodies, but with a low-cost manufacturing process unlike the normal process that requires expensive and special manufacturing equipment. (Click here for more - a subscription may be required
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.